{"name":"iLeukon Therapeutics, Inc.","slug":"ileukon-therapeutics-inc","ticker":"","exchange":"","domain":"ileukon.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOQlVlWVVZVUw1NmpoV2dfN2tTWk1IRzYwQ2dZNWpPQTVPYnJPRGNVWWlvRnltbXJYM2FjdUNZRjZRWVNvYlRPbkkzTnhwWUVxWWx0MEhaWlVfOUh6eWFyQ1B6VzNlalBuUDZ2dGZiZUZONzZEbEtGT0xnV0RmUWNFNXpDRkhBYVA0YlRDZHpmeGdLRDNOR09uOHQzOHVEVWtPQkxaM2JxQ3NieDNyVm8wLUEwaGhGNVRKN3pzX2pKVkVSQQ?oc=5","date":"2025-11-11","type":"trial","source":"PR Newswire","summary":"iLeukon Therapeutics Presents Phase I Data for ILKN421H at SITC 2025 - PR Newswire","headline":"iLeukon Therapeutics Presents Phase I Data for ILKN421H at SITC 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPZUJQN2QtZk03aFo5bmc2RXlFY1kzSHJuUzU2Tzh3OTNPNzdnV09PRG1VQkFTaTFDSzdHOUVCcDNMYjhEcVlpeHVad1lCYmludzJkRTY2UmJqZnc2MWlLOXg4bkNBN0tOSExvcTdKaGl2WnpWdzFxOVBUSkRCQUQybHhodTY0MEQtQWZpcHkwU2x1MnhwVU9qMFJRby1zMU5tZGI1ZDg5OGdoVWpIZEdmRFRwSExwaG14V0pMeGNkN1NYb1Zn?oc=5","date":"2025-11-05","type":"trial","source":"BioPharma APAC","summary":"iLeukon’s mRNA IL-2 Therapy ILKN421H Achieves 80% Response Rate in Lung Cancer Trial - BioPharma APAC","headline":"iLeukon’s mRNA IL-2 Therapy ILKN421H Achieves 80% Response Rate in Lung Cancer Trial","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}